The company reiterates guidance for FY 2023 at CER, based on the average foreign exchange rates through 2022, for total revenue to increase by a low-to-mid single-digit percentage; Excluding COVID-19 medicines, total revenue is expected to increase by a low double-digit percentage. Core EPS is expected to increase by a high single-digit to low double-digit percentage.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca (NASDAQ:AZN) Soars on Q2 Beat; Enters Into $1B Gene Therapy Deal with Pfizer (NYSE:PFE)
- AstraZeneca says Soliris approved in EU for children with refractory gMG
- AstraZeneca: Enhertu showed clinically meaningful PFS, OS in DESTINY-PanTumor02
- Is AZN a Buy, Before Earnings?
- Pfizer price target lowered to $42 from $43 at Morgan Stanley